Skip to content

Released Mar 1, 2024, before the open

10-K filed Mar 1, 2024, 61 days after period end · 0001628280-24-008116

Q4 2023 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$0.00derivedno prior Q4 2022 on fileno prior Q3 2023 on file
Net Income-$65.64MderivedN/M vs Q4 2022N/M vs Q3 2023
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$68,043,000N/M
Operating Cash Flowderived-$43,864,000N/M
Free Cash Flowderived-$45,704,000N/M

What the release said

The release

Same quarter

MetricQ4 2023derived from reported figuresQ4 2022derived from reported figuresQ4 2021derived from reported figures
Revenue$0.00——
Net Income-$65.64M-$39.28M-$62.91M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Prime Medicine, Inc. · CIK 1894562 · Engraved from SEC EDGAR